English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

18 F-DCFPyL, 18 F-sodium fluoride ( 18 F-NaF), and 18 F-FDG PET/CT were compared in a prospective cohort of men with metastatic prostate cancer (PCa). Methods: Sixty-seven men (group 1) with documented metastatic PCa underwent 18 F-DCFPyL and 18 F-NaF PET/CT and a subgroup of 30 men (group 2) underwent additional imaging with 18 F-FDG PET/CT. The tracers were compared for their detection rates, imaging concordance, associations with prostate-specific antigen (PSA), treatment at the time of imaging, and castration status. Results: Overall, 61 men had metastatic disease detected on one or more scans, and 6 men had no disease uptake on any of the PET/CT scans (and were subsequently excluded from the analysis). In group 1, 18 F-NaF detected significantly more metastatic lesions than 18 F-DCFPyL (median of 3 lesions vs. 2, P = 0.001) even after eliminating benign causes of 18 F-NaF uptake. This difference was particularly clear for men receiving treatment ( P = 0.005) or who were castration-resistant ( P = 0.014). The median percentage of bone lesions that were concordant on 18 F-DCFPyL and 18 F-NaF was 50%. In group 2, 18 F-DCFPyL detected more lesions than 18 F-FDG (median of 5 lesions vs. 2, P = 0.0003), regardless of PSA level, castration status, or treatment. The median percentage of lesions that were concordant on 18 F-DCFPyL and 18 F-FDG was 22.2%. This percentage was slightly higher for castration-resistant than castration-sensitive men ( P = 0.048). Conclusion:  18 F-DCFPyL PET/CT is the most versatile of the 3 PET agents for metastatic PCa; however, 18 F-NaF detects more bone metastases. Imaging reveals substantial tumor heterogeneity with only 50% concordance between 18 F-DCFPyL and 18 F-NaF and 22% concordance for 18 F-DCFPyL and 18 F-FDG. These findings indicate considerable phenotypic differences among metastatic lesions.

A comparison of 18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer

A comparison of ¹⁸F-DCFPyL, ¹⁸F-NaF and ¹⁸F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer